Literature DB >> 10780879

Soft tissue sarcomas and p53 mutations.

H Taubert1, A Meye, P Würl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 10780879      PMCID： PMC2230279     

Source DB:  PubMed          Journal:  Mol Med        ISSN： 1076-1551            Impact factor:   6.354


× No keyword cloud information.
  82 in total

1.  Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding.

Authors:  E Shaulian; A Zauberman; D Ginsberg; M Oren
Journal:  Mol Cell Biol       Date:  1992-12       Impact factor: 4.272

2.  Thymocyte apoptosis induced by p53-dependent and independent pathways.

Authors:  A R Clarke; C A Purdie; D J Harrison; R G Morris; C C Bird; M L Hooper; A H Wyllie
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

3.  p53 is required for radiation-induced apoptosis in mouse thymocytes.

Authors:  S W Lowe; E M Schmitt; S W Smith; B A Osborne; T Jacks
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

4.  Amplification of a gene encoding a p53-associated protein in human sarcomas.

Authors:  J D Oliner; K W Kinzler; P S Meltzer; D L George; B Vogelstein
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

5.  Gain of function mutations in p53.

Authors:  D Dittmer; S Pati; G Zambetti; S Chu; A K Teresky; M Moore; C Finlay; A J Levine
Journal:  Nat Genet       Date:  1993-05       Impact factor: 38.330

6.  p53 mutations and aflatoxin B1 exposure in hepatocellular carcinoma patients from Thailand.

Authors:  M C Hollstein; C P Wild; F Bleicher; S Chutimataewin; C C Harris; P Srivatanakul; R Montesano
Journal:  Int J Cancer       Date:  1993-01-02       Impact factor: 7.396

7.  MDM2 gene amplification in metastatic osteosarcoma.

Authors:  M Ladanyi; C Cha; R Lewis; S C Jhanwar; A G Huvos; J H Healey
Journal:  Cancer Res       Date:  1993-01-01       Impact factor: 12.701

8.  The role of multimodality therapy in soft-tissue sarcoma.

Authors:  M F Brennan; E S Casper; L B Harrison; M H Shiu; J Gaynor; S I Hajdu
Journal:  Ann Surg       Date:  1991-09       Impact factor: 12.969

9.  p53 mutations increase resistance to ionizing radiation.

Authors:  J M Lee; A Bernstein
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

10.  mdm2 expression is induced by wild type p53 activity.

Authors:  Y Barak; T Juven; R Haffner; M Oren
Journal:  EMBO J       Date:  1993-02       Impact factor: 11.598
View more
  10 in total

1.  Do Mesenchymal Stem Cells Derived From Atypical Lipomatous Tumors Have Greater Differentiation Potency Than Cells From Normal Adipose Tissues?

Authors:  Hiroyuki Inatani; Norio Yamamoto; Katsuhiro Hayashi; Hiroaki Kimura; Akihiko Takeuchi; Shinji Miwa; Takashi Higuchi; Kensaku Abe; Yuta Taniguchi; Satoshi Yamada; Kiyofumi Asai; Takanobu Otsuka; Hiroyuki Tsuchiya
Journal:  Clin Orthop Relat Res       Date:  2017-02-02       Impact factor: 4.176

Review 2.  TP53 in bone and soft tissue sarcomas.

Authors:  Elizabeth Thoenen; Amanda Curl; Tomoo Iwakuma
Journal:  Pharmacol Ther       Date:  2019-07-02       Impact factor: 12.310

3.  In vivo analysis of mammary and non-mammary tumorigenesis in MMTV-cyclin D1 transgenic mice deficient in p53.

Authors:  Y Hosokawa; A Papanikolaou; R D Cardiff; K Yoshimoto; M Bernstein; T C Wang; E V Schmidt; A Arnold
Journal:  Transgenic Res       Date:  2001-10       Impact factor: 2.788

4.  Uncoupling cancer mutations reveals critical timing of p53 loss in sarcomagenesis.

Authors:  Nathan P Young; Denise Crowley; Tyler Jacks
Journal:  Cancer Res       Date:  2011-04-21       Impact factor: 12.701

5.  An observational study on the expression levels of MDM2 and MDMX proteins, and associated effects on P53 in a series of human liposarcomas.

Authors:  Nader Touqan; Christine P Diggle; Edlo T Verghese; Sarah Perry; Kieran Horgan; William Merchant; Rashida Anwar; Alexander F Markham; Ian M Carr; Rajgopal Achuthan
Journal:  BMC Clin Pathol       Date:  2013-12-13

6.  A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas.

Authors:  Varun Monga; Umang Swami; Munir Tanas; Aaron Bossler; Sarah L Mott; Brian J Smith; Mohammed Milhem
Journal:  Cancers (Basel)       Date:  2018-02-17       Impact factor: 6.639

7.  Correlation of High-Risk Soft Tissue Sarcoma Biomarker Expression Patterns with Outcome following Neoadjuvant Chemoradiation.

Authors:  John M Kane; Anthony Magliocco; Qiang Zhang; Dian Wang; Alex Klimowicz; Jonathan Harris; Jeff Simko; Thomas DeLaney; William Kraybill; David G Kirsch
Journal:  Sarcoma       Date:  2018-02-28

8.  Biological indicators of chemoresistance: an ex vivo analysis of γH2AX and p53 expression in feline injection-site sarcomas.

Authors:  Yike Bing; Zacharie Wund; Tina Abratte; Lucia Borlle; Susie Kang; Teresa Southard; Kelly R Hume
Journal:  Cancer Cell Int       Date:  2018-11-22       Impact factor: 5.722

9.  Cell-Free DNA Variant Sequencing Using Plasma and AR-V7 Testing of Circulating Tumor Cells in Prostate Cancer Patients.

Authors:  Verena Lieb; Amer Abdulrahman; Katrin Weigelt; Siegfried Hauch; Michael Gombert; Juan Guzman; Laura Bellut; Peter J Goebell; Robert Stöhr; Arndt Hartmann; Bernd Wullich; Helge Taubert; Sven Wach
Journal:  Cells       Date:  2021-11-18       Impact factor: 6.600

10.  Molecular approaches to sarcoma therapy.

Authors:  R J Olsen; S R Tarantolo; S H Hinrichs
Journal:  Sarcoma       Date:  2002
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.